Every material event, decoded in plain English — what each one means for the stock.
AllSight quality score: 30/100 — a percentile rank of Revolution Medicines, Inc.’s fundamentals against Manufacturing peers, weakest on growth. A quality ranking, not a price prediction.
| EV / EBITDA | -27.8× |
| Return on equity | -67.8% |
| ROIC | -71.4% |
| Debt / equity | 0.2× |
Valuation today: P/B looks overvalued vs its 5-year range.
Independent of the events above — derived from Revolution Medicines, Inc.’s own financial statements and shown as context, never as advice.